Stock analysis for Cell Source Inc (D:US) including stock price, stock chart, company news, key statistics, fundamentals and company profile. ATCC is a nonprofit organization that collects, stores, and distributes standard reference microorganisms, cell lines, and other materials for research and. If Excel finds a match between the text in the cells, and our online sources, it will convert your text to the Stocks data type. You'll know they're. Free CELL SOURCE INC (CLCS) analysis tools, including analyst ratings and target price forecasts, help you make informed investment decisions. Discover real-time Cell Source Inc (CLCS) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions.
Valuation: Cell Source Inc ; P/E ratio · EV / Sales · Yield *. Cell Source (CLCS) Stock Price & Analysis Looking for Penny Stock ideas? Try our Penny Stock Screener. Explore Now. Cell Source Inc. ; Open. $ Previous Close$ ; YTD Change. %. 12 Month Change. 15,% ; Day Range · 52 Wk Range - Stock Information ; Allogene Therapeutics, Inc. ALLO, M ; Atara Biotherapeutics, Inc. ATRA, M ; bluebird bio, Inc. BLUE, M ; Fate Therapeutics, Inc. Unique to katten-agency.ru, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Results are interpreted as. Cell Source, Inc. (CLCS) ; Aug 2, , , , , ; Aug 1, , , , , Stock analysis for Cell Source Inc (CLCS:OTC US) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Cell Source, Inc. is a cell therapy company focused on immunotherapy. The Company is primarily focused on the development of immune system management. Home · Investing · Stocks · USA · USOTC · Cell Source Inc (PK) (CLCS). Cell Source Inc (PK) (CLCS) Financials. Cell Source Inc (PK). CLCS Cell Source Inc. Get the latest Cell Source Inc (CLCS) real-time quote, historical performance, charts, and other financial information to help you make more informed. Get the latest insights on Cell Source Inc (CLCS) with press releases and corporate news to help you in your trading and investing decisions.
Cell Source Inc ; Prev. Close. ; Low. ; 52wk Low. ; Market Cap. m ; Total Shares. m. Cell Source, Inc. operates as a cell therapy company focused on immunotherapy. Its Veto Cell technology is a next generation immunotherapy technology that. As of August 12, , Cell Source Inc had a $ million market capitalization, putting it in the 18th percentile of companies in the Biotechnology & Medical. US Stock MarketDetailed Quotes. CLCS CELL SOURCE INC. 15min Delay Close Jul 19 ET. %. Market CapK. P/E (TTM) High. Key Stats · Market CapM · Shares OutM · 10 Day Average Volume8, · Dividend- · Dividend Yield- · Beta · YTD % Change Cell Source, Inc. (CLCS) latest earnings report: revenue, EPS, surprise, history, news and analysis. Discover real-time Cell Source Inc (CLCS) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stock Information. SHARE PRICE: $ VOLUME: 4, MARKET CAP: $18,, SHARE COUNT: 41,, DAILY HIGH: $ DAILY LOW: $ OPEN: $ Get Cell Source Inc (CLCS:OTCPK) real-time stock quotes, news, price and financial information from CNBC.
Learn about the Cell Source, Inc. stock splits. Cell Source, Inc. splits history and how its affected shareholders and long-term investors. View the latest Cell Source Inc. (CLCS) stock price, news, historical charts, analyst ratings and financial information from WSJ. Preferred stock is a special equity security that has properties of both equity and debt. Cell Source's preferred stock for the quarter that ended in Mar. You can get stock and geographic data in Excel. It's as easy as typing text into a cell, and converting it to the Stocks data type, or the Geography data type. Cell Source, Inc., a biotechnology company, engages in developing cell therapy treatments based on the management of immune tolerance.
Information on stock, financials, earnings, subsidiaries, investors, and executives for Cell Source. Use the PitchBook Platform to explore the full profile.